The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
For Trump, markets matter more than polls. Luke Broadwater, White House correspondent for The New York Times, examines how Wall Street guides decisions.
As political and economic uncertainty rises, Americans are seeking second passports and golden visas. Latitude Group’s CEO explains what’s driving the surge.
As AI and electrification drive record power demand, nuclear energy returns to the spotlight. Lightbridge CEO explains how advanced fuel could reshape the grid.
Shark Tank’s Kevin O’Leary breaks down his Hollywood debut, Marty Supreme’s $100M box office run, Oscar buzz, and what business taught him about movies.
